Secretion of functional human enzymes by Tetrahymena thermophila by Weide, Thomas et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Biotechnology
Open Access Research article
Secretion of functional human enzymes by Tetrahymena 
thermophila
Thomas Weide†1, Lutz Herrmann†1, Ulrike Bockau1,2, Nadine Niebur1,2, 
Ingo Aldag1, Wouter Laroy3, Roland Contreras3, Arno Tiedtke2 and 
Marcus WW Hartmann*1,2
Address: 1Cilian AG, Johann-Krane-Weg 42, D-48149 Münster, Germany, 2Institut für allgemeine Zoologie und Genetik, Universität Münster, 
Schlossplatz 5, D-48149 Münster, Germany and 3Department of Molecular Biology Research, Unit for Fundamental and Applied Molecular 
Biology, Ghent and Flanders Interuniversity Institute for Biotechnology, Technologiepark 927, B-9052 Ghent, Belgium
Email: Thomas Weide - weide@cilian.de; Lutz Herrmann - herrmann@cilian.de; Ulrike Bockau - bockau@cilian.de; 
Nadine Niebur - niebur@cilian.de; Ingo Aldag - aldag@cilian.de; Wouter Laroy - Wouter.Laroy@dmbr.UGent.be; 
Roland Contreras - Roland.Contreras@dmbr.UGent.be; Arno Tiedtke - tiedtke@uni-muenster.de; 
Marcus WW Hartmann* - hartmann@cilian.de
* Corresponding author    †Equal contributors
Abstract
Background: The non-pathogenic ciliate Tetrahymena thermophila is one of the best-characterized
unicellular eucaryotes used in various research fields. Previous work has shown that this unicellular
organism provides many biological features to become a high-quality expression system, like
multiplying to high cell densities with short generation times in bioreactors. In addition, the
expression of surface antigens from the malaria parasite Plasmodium falciparum and the ciliate
Ichthyophthirius multifiliis suggests that T. thermophila might play an important role in vaccine
development. However, the expression of functional mammalian or human enzymes remains so far
to be seen.
Results: We have been able to express a human enzyme in T. thermophila using expression
modules that encode a fusion protein consisting of the endogenous phospholipase A1 precursor and
mature human DNaseI. The recombinant human enzyme is active, indicating that also disulfide
bridges are correctly formed. Furthermore, a detailed N-glycan structure of the recombinant
enzyme is presented, illustrating a very consistent glycosylation pattern.
Conclusion: The ciliate expression system has the potential to become an excellent expression
system. However, additional optimisation steps including host strain improvement as wells as
measures to increase the yield of expression are necessary to be able to provide an alternative to
the common E. coli and yeast-based systems as well as to transformed mammalian cell lines.
Background
Throughout the last decades the ciliate Tetrahymena ther-
mophila has been used as the model system of choice in
many areas of molecular, cell and developmental biology
[1-4]. For example milestone discoveries like ribozymes
that enable RNA-mediated catalysis [5], the basic analysis
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of dynein motors [6], the finding of telomeres and telom-
erases [7,8] and the function of histone acetyltransferases
in transcription were made in Tetrahymena. Very recently,
the discovery of small scan RNA elucidates the role of
RNAi mediated genome rearrangement [9].
In previous experiments T. thermophila has been used to
express proteins of two phylogenetic closely related alveo-
late species. Gaertig et al. showed expression of the I-anti-
gen of the ciliate Ichthyophthirius multifiliis, a parasite that
causes the white spot disease of freshwater fish [10,11].
Later on it could be demonstrated that the GPI-anchored
circumsporozoite (CS) protein of the malaria parasite
Plasmodium falciparum, was expressed and targeted to the
surface of T. thermophila. Consequently, T. thermophila
could also play an important role in strategies for vaccine
development [12]. All three protozoans Tetrahymena ther-
mophila, Ichthyophthirius multifiliis as well as the malaria
parasite Plasmodium falciparum belong to the alveolates, a
distinct phylogenetic group that includes ciliates, apicom-
plexans and dinoflagellates. They are characterised by
both very AT-rich genomes and an unusual codon usage
[13-16]. However, so far the expression of functional
mammalian or human proteins in T. thermophila remains
to be shown.
The  T. thermophila genome has just been completely
sequenced by an NIH program and can now be used for
thorough proteome analysis (The Institute for Genomic
Research [17]). Furthermore, it is known that T. ther-
mophila cells grow fast to high cell densities in inexpensive
media and simple bioreactor infrastructure [18,19]. Over-
all, these are the basis for developing an excellent expres-
sion system and using the ciliate T. thermophila for
biotechnology applications [20]. In contrast to the previ-
ously done expression experiments here we report for the
first time the heterologous expression of a human enzyme
that subsequently is secreted into the surrounding
medium.
We selected the human DNaseI to demonstrate that T.
thermophila as an expression host is able to produce func-
tional human enzymes. Human DNase I is a 29.3 kD glyc-
oprotein with two N-glycosylation sites at Asn18  and
Asn106 and two calcium ion binding sites. One of two
intrachenar disulfide bridges (Cys101/Cys104 and Cys173/
Cys209) is crucial for enzyme activity [21]. Aging of the
beta-sandwich shaped enzyme is accompanied by deami-
dation of Asn74 thereby reducing enzyme activity and
facilitating degradation of the protein [22]. Interestingly,
recombinant human DNase I produced in CHO cells
(Pulmozyme®, Roche) is administered to patients with
cystic fibrosis by inhalation in order to reduce sputum vis-
coelasticity and to improve lung function.
Results
Expression and secretion of functional human DNase I by 
T. thermophila
Aim of this study was to show that T. thermophila is capa-
ble of expressing a human enzyme which is secreted under
the control of an endogenous T. thermophila derived pre-
cursor peptide. The codon bias of ciliates has been ana-
lysed in detail [13,15,16]. In summary it is quite different
from human genes. 15 of the 63 possible codons in
human DNase I are very rare codons in T. thermophila
according to the definition of Wutschick and Karrer: A rare
codon is a codon that is no more than 10% of the total
and less than 50% of the fraction expected if all synonyms
are used at equal frequency. As an example, codons that
encode arginine illustrate this problem. From six possible
codons only AGA is preferentially used in highly
expressed genes (96%) in T. thermophila. The other five
codons AGG, CGA, CGC, CGG and CGU are only used in
less than 5% of the total arginine codons and especially
the CGG codon is very rare. The original human DNaseI
sequence (accession number: NM_005223) consists of 14
arginines, but only two of the human original codons are
optimal for expression in the T. thermophila host system.
As both groups Wutschick and Karrer as well as Larsen et
al. report a correlation between frequently used codons
and a higher expression level of genes that contain these
codons we used a synthetic "codon-adapted" DNaseI gene
to avoid problems in expression.
The synthetic optimised gene encodes the human 282
amino acids (aa) of the human precursor of DNase I
(accession number: DQ073047). In summary 67% of all
codons (188 of 282) were changed into codons that are
frequently used in T. thermophila. From the 188 optimised
codons more than 50% (97 of 188) are changed at the
third position. Only one third (93 of 282) of the original
sequence seemed to be suitable to express a human
enzyme in the ciliate. The original human DNase I cDNA
and the codon adapted sequence are compared in figure
1. In our experiments we want to express and secrete the
human DNaseI by a ciliate system. Therefore we con-
structed expression cassettes that encode parts of the pre-
cursor sequence of the PLA1 (phospholipase A1) gene
(accession number: AJ508393) and the mature human
DNaseI (aa 23 to 281) of the synthetic gene [23]. The PLA1
prepro-peptide has significant similarity to members of
the cathepsin L family and mediates secretion into the
medium [24]. We have previously characterized the cleav-
age site between the pro-peptide and the mature enzyme
to be between aa 110 and 111 by sequencing of the N-ter-
minus of the mature PLA1 enzyme (unpublished data).
The first fusion protein encodes the PLA1 signal peptide as
determined by SignalP [25] (aa 1–23 of PLA1), an addi-
tional 13 amino acid spacer (aa 24–36 of PLA1) and the
mature DNaseI (aa 23 to 281 encoded by the syntheticBMC Biotechnology 2006, 6:19 http://www.biomedcentral.com/1472-6750/6/19
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Codon adaptation of the used synthetic DNase I gene Figure 1
Codon adaptation of the used synthetic DNase I gene. As the codon bias of T. thermophila is different from that of 
human genes 67% of 283 coding triplets of the original human codons (WT) were changed into codons that are known to be 
mostly present in highly expressed T. thermophila genes (CO) [13,16]. The adapted codons are marked by gray boxes. The cor-
responding amino acid sequence is given in single letter code; N-glycosylation sites are highlighted in bold letters, cysteines 
forming disulfide bridges are underlined.
WT ATG AGG GGC ATG AAG CTG CTG GGG GCG CTG CTG GCA CTG GCG GCC CTA CTG CAG GGG GCC   60
CO ATG AGA GGT ATG AAG TTG CTC GGT GCT TTA TTA GCC CTT GCT GCT CTT TTA TAA GGT GCT
M   R   G   M   K   L   L   G   A   L   L   A   L   A   A   L   L   Q   G   A
WT GTG TCC CTG AAG ATC GCA GCC TTC AAC ATC CAG ACA TTT GGG GAG ACC AAG ATG TCC AAT  120
CO GTT TCC TTA AAG ATC GCT GCT TTC AAC ATC CAA ACT TTC GGT GAA ACT AAG ATG TCT AAC
V   S   L   K   I   A   A   F   N   I   Q   T   F   G   E   T   K   M   S N
WT GCC ACC CTC GTC AGC TAC ATT GTG CAG ATC CTG AGC CGC TAT GAC ATC GCC CTG GTC CAG  180
CO GCT ACC CTC GTT TCT TAT ATC GTC CAA ATT CTC TCC AGA TAT GAT ATT GCT CTC GTC TAA
A   T   L   V   S   Y   I   V   Q   I   L   S   R   Y   D   I   A   L   V   Q
WT GAG GTC AGA GAC AGC CAC CTG ACT GCC GTG GGG AAG CTG CTG GAC AAC CTC AAT CAG GAT  240
CO GAA GTT AGA GAT TCT CAT CTC ACC GCC GTC GGT AAG CTT CTT GAT AAT TTG AAC TAA GAC
E   V   R   D   S   H   L   T   A   V   G   K   L   L   D   N   L   N   Q   D
WT GCA CCA GAC ACC TAT CAC TAC GTG GTC AGT GAG CCA CTG GGA CGG AAC AGC TAT AAG GAG  300
CO GCT CCC GAT ACC TAT CAC TAC GTC GTC TCT GAA CCC TTG GGT AGA AAC TCT TAT AAG GAA
A   P   D   T   Y   H   Y   V   V   S   E   P   L   G   R   N   S   Y   K   E
WT CGC TAC CTG TTC GTG TAC AGG CCT GAC CAG GTG TCT GCG GTG GAC AGC TAC TAC TAC GAT  360
CO AGA TAC TTA TTC GTT TAC AGA CCC GAC CAA GTC TCT GCT GTC GAT TCC TAC TAC TAT GAT
R   Y   L   F   V   Y   R   P   D   Q   V   S   A   V   D   S   Y   Y   Y   D
WT GAT GGC TGC GAG CCC TGC GGG AAC GAC ACC TTC AAC CGA GAG CCA GCC ATT GTC AGG TTC  420
CO GAT GGT TGC GAA CCT TGC GGT AAT GAT ACC TTC AAC AGA GAA CCT GCC ATC GTT AGA TTC
D   G   C   E   P   C   G N   D   T   F   N   R   E   P   A   I   V   R   F
WT TTC TCC CGG TTC ACA GAG GTC AGG GAG TTT GCC ATT GTT CCC CTG CAT GCG GCC CCG GGG  480
CO TTC TCT AGA TTC ACC GAA GTC AGA GAA TTC GCT ATC GTC CCC TTA CAC GCT GCC CCC GGT
F   S   R   F   T   E   V   R   E   F   A   I   V   P   L   H   A   A   P   G
WT GAC GCA GTA GCC GAG ATC GAC GCT CTC TAT GAC GTC TAC CTG GAT GTC CAA GAG AAA TGG  540
CO GAC GCC GTT GCT GAA ATC GAT GCT TTG TAC GAT GTT TAC CTC GAT GTC CAA GAA AAG TGG
D   A   V   A   E   I   D   A   L   Y   D   V   Y   L   D   V   Q   E   K   W
WT GGC TTG GAG GAC GTC ATG TTG ATG GGC GAC TTC AAT GCG GGC TGC AGC TAT GTG AGA CCC  600
CO GGT CTC GAA GAT GTT ATG TTG ATG GGT GAC TTC AAC GCT GGT TGC TCC TAC GTT AGA CCT
G   L   E   D   V   M   L   M   G   D   F   N   A   G   C   S   Y   V   R   P
WT TCC CAG TGG TCA TCC ATC CGC CTG TGG ACA AGC CCC ACC TTC CAG TGG CTG ATC CCC GAC  660
CO TCT CAA TGG TCC TCC ATC AGA TTG TGG ACT TCC CCC ACT TTC CAA TGG TTA ATT CCT GAT
S   Q   W   S   S   I   R   L   W  T   S   P   T   F   Q   W   L   I   P   D
WT AGC GCT GAC ACC ACA GCT ACA CCC ACG CAC TGT GCC TAT GAC AGG ATC GTG GTT GCA GGG  720
CO TCC GCT GAT ACC ACT GCT ACC CCC ACT CAC TGT GCC TAC GAT AGA ATT GTC GTC GCT GGT
S   A   D   T   T   A   T   P   T   H   C   A   Y   D   R   I   V   V   A   G
WT ATG CTG CTC CGA GGC GCC GTT GTT CCC GAC TCG GCT CTT CCC TTT AAC TTC CAG GCT GCC  780
CO ATG CTT CTC AGA GGT GCC GTC GTC CCC GAC TCC GCT CTT CCC TTC AAC TTC CAA GCT GCT
M   L   L   R   G   A   V   V   P   D   S   A   L   P   F   N   F   Q   A   A
WT TAT GGC CTG AGT GAC CAA CTG GCC CAA GCC ATC AGT GAC CAC TAT CCA GTG GAG GTG ATG  840
CO TAC GGT CTT TCC GAC TAA CTC GCT CAA GCC ATT TCT GAC CAC TAC CCT GTC GAA GTC ATG
Y   G   L   S   D   Q   L   A   Q   A   I   S   D   H   Y   P   V   E   V   M
WT CTG AAG TGA 849
CO TTG AAG TGA
L   K   -BMC Biotechnology 2006, 6:19 http://www.biomedcentral.com/1472-6750/6/19
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Expression of functional human DNaseI Figure 2
Expression of functional human DNaseI. a: The structure concept of the expression cassettes. For all expression cas-
settes we used the cell-cycle dependent H4-1 histone or the Cd-inducible MTT1 promotor and the beta tubulin 2 (BTU2) ter-
minator sequence. Selection was done by the neo resistance gene (neoR). Secretion of the rhDNase was regulated by parts of 
the endogenous precursor of PLA1. We used the first 36, 110 and 115 amino acids of the PLA-precursor. The mature human 
DNase I corresponds to the aa 23–281. b: We obtained an anti DNaseI serum by using CHO derived DNase I (Pulmozyme) as 
an antigen. After that the serum was tested by western blot using de-glycosylated DNaseI (PNGaseF treated, F+ lane1) as well 
as the glycosylated protein. No significant difference in the signal strength could be observed, suggesting that the N-glycan 
structure of rhDNase has no, or only a minor influence on the avidity of the serum. c: Secretion of processed recombinant 
human DNaseI into the media. Lane1: 20 µl supernatant of the T. thermophila wildtype strain B1868.7, negative control; Lane2: 
20 µl supernatant of mock-(EGFP) transformed T. thermophila; Lane 3–5: 20 µl supernatant of T. thermophila cells that were 
transformed with expression plasmids, carrying the spPLA36, ppPLA110 and ppPLA115 prepro-peptides, respectively. d: Determi-
nation of DNase activity in 10 µl supernatant of transformed T. thermophila. Control: mock-(EGFP) expressing cells; Histone: 
cell cycle dependent expression of ppPLA115; MTT1: inducible expression of ppPLA115; (MTT1-Cd: non-induced; MTT1 + Cd: 
induced). e: Different amounts of rhDNaseI from CHO cells (1.0, 2.5 and 5.0 ng) were used to roughly quantify the yield of 
rhDNase in 30 µl ppPLA115 supernatant of T. thermophila. f: Demonstration of up-scalability by comparing cell titres during 50 
litre fermentation (black) and 400 ml shaker flask cultivation (gray) of rhDNase I secreting T. thermophila.
a Structure of expression cassettes b Influence of glycosylation
on serum avidity
c Secretion of rhDNase I d Activity of rhDNase I
e Quantification of rhDNase I f Up-scalability of cultivation
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gene). The second hybrid protein consists of the whole
prepro-peptide of PLA1 (aa 1–110) and the mature DNa-
seI. The third cassette is similar to the second except for
the first five amino acids of the secreted mature PLA1 (sin-
gle letter code GEATE; aa 111–115). This cassette was
made to ensure an optimal cleavage of the proPLA1-DNa-
seI fusion protein by endogenous pro-peptidases. The
expression cassettes were cloned into the pH4T2 vector
that consists of two rDNA origins and the neomycin resist-
ance gene (neoR) [26]. Both the neoR gene and the PLA1-
DNasehybrid genes were controlled by the cell-cycle
dependent histone promoter H4-1 and the beta tubulin 2
BTU2 terminator (Figure 2a). We transformed conjugat-
ing T. thermophila with the expression plasmids by electro-
poration, and monitored the successful transformation by
selection against paromomycin. Supernatants of the dif-
ferent cultures were analysed by SDS-PAGE and Western
blot for secretion of the recombinant human DNaseI
(rhDNaseI). All samples analysed expressed and secreted
rhDNaseI, regardless of the length of the PLA1-prepro-
peptide sequence fused to the DNaseI (Figure 2c). Further-
more, all expression modules resulted in rhDNaseI pro-
teins of the same size (~35 kD), indicating the existence of
a processing mechanism that is independent of a con-
served pro-peptidase recognition site, similar to the
known processing of granule lattice proteins of dense core
vesicles in T. thermophila [27]. A control strain that
expresses and secretes EGFP and the non-transformed T.
thermophila wild type strain B1868.7 was used. Superna-
tants of cells expressing the ppPLA115-DNase fusion pro-
tein were assayed for DNase activity. Compared to
supernatants of mock-transformed cells a significantly ele-
vated enzyme activity was measured. The heterologous
expression of human DNaseI by T. thermophila was also
analysed by application of the inducible metallothionein-
1 promoter (MTT1) system [28] (Figure 2d). In these
experiments the expression of the ppPLA115-DNase fusion
protein was regulated by the addition of Cadmium to the
medium. The induced cells exhibited a significantly ele-
vated DNase activity in the supernatant. In non-induced
cultures the DNase activity remained – just like expected
– close to the basal level. This clearly argues that the
observed increased DNaseI activity in the supernatant is
due to the secretion of functional rhDNase, confirming
the experiments shown in Figure 2c. The basal activity
measured in the negative control corresponds to at least
two endogenous DNases (data not shown). As rhDNase
combines in one enzyme all assets necessary for develop-
ment of a novel expression system with secretion,
disulfide bridge formation and glycosylation site recogni-
tion the main focus of our initial experiments was to illus-
trate that not only antigens from related species (I.
multifiliis and P. falciparum) but also functional human
enzymes of biotechnological interest can be expressed and
secreted by the ciliate system. Nevertheless, to give a first
and roughly estimation of the yield of secreted rhDNase
we used semi-quantitative Western blotting. Therefore we
generated a polyclonal antiserum against the rhDNaseI
from CHO cells and tested first if the N-glycosylation has
an impact on avidity. Figure 2b clearly illustrates that both
glycosylated DNaseI as well as the de-glycosylated enzyme
display the same signal strength in Western blot analysis,
suggesting that almost all of the antigenic epitopes recog-
nised are on protein level and that the N-glycan structure
plays an unimportant role in avidity. This allows us to give
a first and rough estimation about the amount of the
secreted DNaseI, by semi-quantitative Western blotting.
We found ca. 100 µg rhDNase per litre supernatant fluid
(see Figure 2e; 1 ng/10 µl supernatant). This crudely esti-
mated amount combined with the determined DNase
activity of 400 U per litre supernatant (4 mU/10 µl, see
Figure 2d) means that a "specific" activity can be deter-
mined as ca. 4 Units per µg rhDNase. For most biotechni-
cal applications it is crucial to obtain a first impression
whether or not the cultivation of transformants can be
scaled up. Therefore we tested if the rhDNA secreting
clone is growing in the same way as previously described
for wildtype strains [20,29]. RhDNase I expressing cells
were grown on a small scale (400 ml shaker flask), as well
as in 2 and 50 litre batch fermentations. Figure 2f illus-
trates that growth (up to more than 2 × 106 cells/ml) of
transformants is independent of the culture volume. Fur-
thermore up-scaling does not alter results shown in Figure
2b–d.
Glycosylation pattern on recombinant proteins derived 
from T. thermophila
Transport through the ER and Golgi compartments usu-
ally is accompanied by the addition of N-glycans. We
addressed this point for the recombinant DNaseI and per-
formed band-shift assays by applying N-glycosidase F
(PNgase F) to immunoprecipitated DNaseI from superna-
tant of transformed T. thermophila cells (Figure 3a). An
aliquot of this IP sample (F+) revealed a significant band-
shift on a 15% SDS-gel when compared to the control
without N-glycosidaseF treatment (F-). Glycosylated and
de-glycosylated DNaseI from CHO cells was used as con-
trol. The significant reduction of the molecular weight of
secreted rhDNaseI from T. thermophila demonstrates that
the DNase becomes glycosylated while shuttling through
the ER and Golgi. Furthermore comparison of lane 3 and
5 also shows that the non-glycosylated rhDNase from T.
thermophila and CHO-cells are running at heights of com-
parable molecular weight. Next we applied a Concanava-
lin A (Con A) pulldown assay to test whether the glycans
of secreted rhDNaseI are terminated by N-terminal man-
noses, as described for endogenous secreted enzymes of
Tetrahymena [30,31]. We used the same cell-free superna-
tants as in the IP approach (compare Figure 3a lane 4 and
5). The B1868.7 wildtype supernatant spiked with glyco-BMC Biotechnology 2006, 6:19 http://www.biomedcentral.com/1472-6750/6/19
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N-glycan structure on recombinant secreted human DNase I Figure 3
N-glycan structure on recombinant secreted human DNase I. a: Band-shift assay: rhDNase I from CHO cells and 
secreted rhDNase I from T. thermophila were de-glycosylated. The treatment with PNGase F (F+) results in a significant band-
shift, when compared to the controls (F-), illustrating that the secreted rhDNase I of T. thermophila becomes glycosylated. As T. 
thermophila rhDNase I had been concentrated by immunoprecipitation, additional bands of antibody-chains appear in Western 
blotting. The DNase signals are highlighted by asterisks. b: Concanavalin A pulldown assay: Supernatants of transformed T. ther-
mophila strain and a wildtype strain (B1868.7) were analysed. The supernatant of the wildtype was spiked with equal amounts 
(2 µg) of glycosylated (F-) or de-glycosylated (F+) rhDNase I from CHO cells, respectively. Only mannose-terminated glyco-
sylated rhDNase is recovered by Con A (lane 3), glycosylated (F-) and de-glycosylated rhDNase I (F+) from CHO cells did not 
bind to ConA beads (lanes 1 and 2). c: DSA-FACE N-glycan analysis of T. thermophila rhDNase I: This data illustrates the highly 
consistent N-glycan structure on rhDNaseI produced in T. thermophila. All N-glycans are mannose terminated, as shown by 
digestion with jack bean mannosidase in the lower panel. The most prominent structure is the Man3GlcNAc2 core pattern with 
additional alpha 1,2 bound mannoses (two middle panels). d: DSA-FACE N-glycan analysis of CHO rhDNase I: On the CHO 
derived rhDNase I more than 20 distinct peaks, each corresponding to a different N-glycan, are observed in the untreated 
sample. This typical complex profile of mammalian cells is in sharp contrast to the consistent T. thermophila glycosylation. Even 
removal of terminal N-acetylneuraminic acid by treatment with sialidase still leads to a large number of various glycans (lower 
panel).
123
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sylated and de-glycosylated rhDNaseI from CHO cells was
used as control. We added ConA beads and performed
extensive washes, to avoid unspecific binding. Only the
rhDNaseI from T. thermophila was recovered by the ConA
beads, indicating that it predominantly contains α-Dman-
nose terminated glycosylation chains. The DNaseI from
CHO cells which contains a different, complex N-glycan
feature with terminal galactose, N-acetylglucoseamine or
sialic acid residues and the de-glycosylated rhDNaseI did
not bind to the ConA (Figure 3b). The specificity of the
ConA pulldown assays was nicely confirmed by the DSA-
FACE technology for N-glycan profiling [32]: These results
illustrate that almost all recombinant protein displays a
mannose terminated oligo-glycosylation pattern, compa-
rable to endogenous secreted proteins [30]. The most
prominent N-glycan is the Man3GlcNAc2 structure (Fig-
ure. 3c). All structures can be reduced to ManGlcNAc2
using an unspecific mannosidase, indicating the presence
of mannose only at the core. Overall the T. thermophila
pattern is very consistent (see Figure 3c, second panel).
This consistency is even more obvious when compared to
the typical complex glycosylation of rhDNase I from CHO
cells shown in Figure 3d (see second and third panel).
Discussion
Here we report for the first time the expression and secre-
tion of functional human DNaseI, illustrating that not
only surface proteins from related species but also mam-
malian proteins are potential candidates. To avoid prob-
lems in expression due to the fact that the codon bias in T.
thermophila is quite different to that of mammalian cells
we used a codon adapted gene in which critical triplets
were changed (see figure 1). All hybrid constructs used
lead to expression of the rhDNaseI in T. thermophila. These
results clearly show that the here presented ciliate system
has the high potential to become an attractive alternative
for expression and secretion of complex functional
human proteins. Furthermore, unlike in yeast expression
systems, where hyper-glycosylation causes problems on
recombinant proteins, the rhDNase secreted by T. ther-
mophila carries a consistent, oligo-glycosylated N-glycan
structure [33,34]. Additionally, the predominant
Man3GlcNAc2 sequence on T. thermophila derived proteins
could be an interesting starting point for in vitro glycosyla-
tion to produce homogenous glycoproteins. A well
known problem of bacterial expression systems is the
proper formation of disulfide bridges. As the expression
and secretion of rhDNase I in the free-living protozoan T.
thermophila  yields a highly active enzyme, at least the
required internal disulfide bridge (Cys173-Cys209) must
have formed in the right manner [21].
Conclusion
The roughly estimated yield of 100 µg/L rhDNase I in T.
thermophila  is a promising starting point for further
improvements of this very young expression system.
Established and commonly known systems surely cur-
rently have higher expression rates (e.g. 5 mg/l rhDNaseI
in COS-cells [35]). Yet there are other criteria to be met for
a new expression host to be adopted by the biotech indus-
try like up scalability, simple and inexpensive media,
growing to high cell densities, protease-deficiency and
ease of cell line engineering of the production strains that
all contribute to low cost of manufacturing. In T. ther-
mophila these requirements can be fulfilled because a sim-
ple bioreactor infrastructure is sufficient for production.
Moreover, high cell density fermentation with cell reten-
tion is available in our laboratories [18,29]. The use of
such techniques allows us to obtain cell densities in inex-
pensive media of more than 2.2 × 107 cells/ml, equivalent
to 48 g dry weight, thereby reducing the cost of manufac-
turing. Genetic tools are at hand to increase promoter
activity and to improve strains easily by targeted knock
outs of proteases, random mutagenesis and secretion opti-
misation. These measures will lead to an excellent expres-
sion-secretion system bearing a competitive alternative to
the common and technically mature systems like E. coli,
yeast and transformed mammalian cell lines.
Methods
Strains, cultivation and fermentation
Tetrahymena thermophila strains B1868.4, B1868.7 and B
2068.1 were kindly provided by Peter J. Bruns and culti-
vated in skimmed milk medium (2% skimmed milk,
0.5% yeast extract, 0.1% ferrous sulphate chelate solution
and 1% glucose) on a Braun Certomat BS-1 at 80 rpm and
30°C. For fermentations a Braun UD50 (50 litre) and Bio-
engineering KLF2000 (2 litre) equipped with standard
Rushton impellers were used. Stirrer speed was limited to
300 and 400 rpm respectively; pO2 was set to 25%.
Generation and transformation of expression plasmids
Transformation of cells was performed with plasmids
derived from the pH4T2 vector [26]. For the Cd-inducible
expression the histone promoter in the ppPLA115-con-
struct was substituted by the T. thermophila MTT1-pro-
moter. Metallothioneins, that are upregulated upon stress,
are metal binding proteins playing a role in detoxification
of the cell. In Tetrahymena  the MTT1-promoter can be
induced best by the addition of Cadmium [28]. Cloning
of the expression modules and mutagenesis were per-
formed with standard techniques. To ensure a translation
of the fusion proteins a synthetic, codon optimised
human DNaseI gene was used [13,15]. The synthesis was
performed by a solid phase process described in German
Patent DE 19812103.2 by the company ATG biosynthet-
ics, Merzhausen Germany. In brief oligonucleotides were
specifically annealed 3' at the immobilized single
stranded DNA and extended by a polymerase. A double
strand-specific 5' nuclease digestion enables subsequentBMC Biotechnology 2006, 6:19 http://www.biomedcentral.com/1472-6750/6/19
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annealing of a new primer 3' at the growing synthetic gene
and the cycle starts over. The sequence has been submitted
to genbank (Accession number: DQ073047).
Generation of polyclonal anti human DNase I antibodies 
from rabbit
Recombinant human DNaseI from CHO cells (Pulmo-
zyme®, Roche) was used to generate a specific antiserum
from rabbit against human DNaseI. Affinity purification
using a protein A/protein G mixture was performed in
order to minimize background signals.
SDS-PAGE and Western
The aliquots of SPP supernatants were resuspended in
sample buffer and separated on 15% SDS-PAGE. rhDNa-
seI from CHO cells (Pulmozyme®, Roche) served as refer-
ence. The gels were blotted onto nitrocellulose
membranes and blocked in PBS containing 0.05%
Tween20 and 5% skimmed milk (PBS-TM). The anti-rhD-
NaseI was used in a 1:500 dilution in PBS-TM. After wash-
ing with PBS/T and application of HRP-conjugated anti
rabbit serum the blots were developed using chemilumi-
nescence.
Immunoprecipitation of DNase I from T. thermophila 
supernatants
Anti DNase serum was coupled to cyanogen bromide acti-
vated Sepharose 4B according to the manufacturer's
instructions. T. thermophila supernatants were applied to
the column. After washing with PBS, bound protein was
eluted with 0.1 M HCl-glycin pH2.8 and neutralized with
2 M Tris.
DNase I activity assay
The methyl green based DNase activity assay was per-
formed as already published [36]. Samples were incu-
bated at 37°C for 24 h on a microtiter plate. Absorbance
was measured at 620 nm.
Calibration of the assay was achieved by different
amounts of defined DNase I Units of Pulmozyme® from
Roche (CHO derived) in each experiment and linear
regression. These results combined with semi-quantitative
western blotting were used to calculate the specific activity
of expressed DNase I.
Purification of rhDNase I and N-glycan analysis of 
rhDNase I from recombinant T. thermophila 
supernatants
Purification of the rhDNase I was performed with slight
modifications as described previously [35]. Band-shift
assay: We performed an immunoprecipitation as
described above. An aliquot of the IP sample was de-glyc-
osylated by applying N-glycosidaseF (Roche, Germany)
according to the manufacturer's instructions. The de-glyc-
osylation of rhDNaseI was used to control the glycosyla-
tion assay. Concanavalin pull down assay: We used ConA
coupled to Sepharose 4B beads. The beads were washed
and resuspended in PBS in order to prepare a 50% slurry.
200 µl of the 50% slurry was added to cell-free superna-
tant. The beads were incubated for 3 h under rotation at
room temperature to allow the Con A beads to bind to the
glycosylated proteins. After that, Con A beads were col-
lected by centrifugation (2 min, 1000 × g at 4°C) and sub-
sequently washed in PBS with 1% TritonX-100. All
samples were analysed by SDS-PAGE and Western blot.
DSA-FACE analysis of N-glycans: Purified recombinant
DNaseI from transformed T. thermophila and rhDNase I
from CHO cells were analysed by the DSA-FACE N-glycan
analysis method, as previously described [32]. Enzymatic
digestions (T. reesei alpha 1,2-mannosidase, jack bean
mannosidase and Arthrobacter ureafaciens alpha 2,3/6/8/9-
sialidase) were done in 20 mM NaAc, pH 5.5 for 16 h.
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